• Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients

  • Feb 2 2025
  • Length: 16 mins
  • Podcast

Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients

Listen for free

View show details

  • Summary

  • In this episode, we explore the groundbreaking results of the EMPA-KIDNEY trial, a large-scale clinical study that highlights the long-term benefits of Empagliflozin (SGLT2 inhibitor) in patients with chronic kidney disease (CKD). We dive into how the treatment slowed disease progression, reduced cardiovascular deaths, and provided lasting benefits even after the therapy ended. Join us as we break down the study’s key findings, discuss their real-world implications, and uncover what makes this treatment a game-changer for CKD management.

    🔗 Full Study Details: NEJM - EMPA-KIDNEY Study
    🔗 ClinicalTrials.gov: EMPA-KIDNEY NCT03594110


    Links to the Podcast

    • Apple Podcast: ⁠Listen on Apple Podcast⁠
    • Spotify: ⁠Listen on Spotify⁠
    • Amazon Music: ⁠Listen on Amazon Music⁠
    • YouTube: ⁠Watch on YouTube⁠


    #Podcast #Empagliflozin #ChronicKidneyDisease #CKDManagement #EMPA_KIDNEY_Study #SGLT2Inhibitors #RenalHealth #CardioRenalProtection #ClinicalResearch #MedicalBreakthroughs #LongTermBenefits
    Show More Show Less
Show More Show Less

What listeners say about Empagliflozin’s Impact: Long-Term Cardiorenal Protection for CKD Patients

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.